{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:20:17Z","timestamp":1793661617417,"version":"4.5.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.phrs.2024.107181","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T01:35:13Z","timestamp":1712885713000},"page":"107181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas"],"prefix":"10.1016","volume":"203","author":[{"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2024.107181_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2024.107181_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2024.107181_bib3","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.phrs.2024.107181_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","article-title":"NCCN Guidelines\u00ae insights: kidney cancer, version 2.2024","volume":"22","author":"Motzer","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.phrs.2024.107181_bib5","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/PAS.0b013e318299f2d1","article-title":"The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia","volume":"37","author":"Srigley","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.phrs.2024.107181_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","article-title":"Vascular endothelial growth factor (VEGF) signaling in tumor progression","volume":"62","author":"Roskoski","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2024.107181_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116158","article-title":"Novel small molecule inhibitors targeting renal cell carcinoma: status, challenges, future directions","volume":"267","author":"Xiong","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2024.107181_bib8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbrc.2007.02.156","article-title":"Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor","volume":"356","author":"Roskoski","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2024.107181_bib9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105463","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104725","article-title":"The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias","volume":"155","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib19","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1358\/dot.2005.41.12.937959","article-title":"Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment","volume":"41","author":"Strumberg","year":"2005","journal-title":"Drugs Today"},{"key":"10.1016\/j.phrs.2024.107181_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2024.107181_bib21","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2024.107181_bib22","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1358\/dot.2006.42.6.985633","article-title":"Sunitinib: a newly approved small-molecule inhibitor of angiogenesis","volume":"42","author":"Cabebe","year":"2006","journal-title":"Drugs Today"},{"key":"10.1016\/j.phrs.2024.107181_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/01.mou.0000240305.78205.77","article-title":"New treatment approaches in metastatic renal cell carcinoma","volume":"16","author":"Mancuso","year":"2006","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.phrs.2024.107181_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd3073","article-title":"Pazopanib","volume":"9","author":"Bukowski","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107181_bib25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4137\/CMO.S7263","article-title":"Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib","volume":"5","author":"Vasudev","year":"2011","journal-title":"Clin. Med. Insights Oncol."},{"key":"10.1016\/j.phrs.2024.107181_bib26","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2024.107181_bib27","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107181_bib28","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.2147\/OTT.S97397","article-title":"Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection","volume":"9","author":"Yu","year":"2016","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.phrs.2024.107181_bib29","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2024.107181_bib30","first-page":"139","article-title":"Tivozanib in the treatment of renal cell carcinoma","volume":"7","author":"Hepgur","year":"2013","journal-title":"Biologics"},{"key":"10.1016\/j.phrs.2024.107181_bib31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/1078-0432.CCR-21-2334","article-title":"FDA approval summary: tivozanib for relapsed or refractory renal cell carcinoma","volume":"28","author":"Chang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2024.107181_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106037","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update","volume":"175","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-024-06547-3","article-title":"mTOR pathway occupies a central role in the emergence of latent cancer cells","volume":"15","author":"Aleksandrova","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2024.107181_bib34","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1002\/cncr.24409","article-title":"Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma","volume":"115","author":"Kapoor","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2024.107181_bib35","doi-asserted-by":"crossref","first-page":"34495","DOI":"10.1074\/jbc.C800170200","article-title":"Differential dependence of hypoxia-inducible factors 1\u03b1 and 2\u03b1 on mTORC1 and mTORC2","volume":"283","author":"Toschi","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2024.107181_bib36","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2024.107181_bib37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2024.107181_bib38","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2024.107181_bib39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2024.107181_bib40","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tibs.2015.09.002","article-title":"Dynamics-driven allostery in protein kinases","volume":"40","author":"Kornev","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2024.107181_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100746","article-title":"From structure to the dynamic regulation of a molecular switch: a journey over 3 decades","volume":"296","author":"Taylor","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2024.107181_bib42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib43","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bioorg.2011.07.004","article-title":"Protein kinase biochemistry and drug discovery","volume":"39","author":"Schwartz","year":"2011","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2024.107181_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib45","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2024.107181_bib46","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2024.107181_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2024.107181_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105660","article-title":"Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes","volume":"169","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106552","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update","volume":"187","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib51","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2024.107181_bib52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tibs.2009.11.005","article-title":"How antibodies fold","volume":"35","author":"Feige","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2024.107181_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41568-023-00637-8","article-title":"Fc\u03b3 receptors and immunomodulatory antibodies in cancer","volume":"24","author":"Galvez-Cancino","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2024.107181_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101480","article-title":"Emerging concepts in PD-1 checkpoint biology","volume":"52","author":"Pauken","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.phrs.2024.107181_bib55","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/cr.2016.77","article-title":"Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab","volume":"27","author":"Na","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.phrs.2024.107181_bib56","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21037\/tau-23-588","article-title":"The final report of KEYNOTE-426 showed the efficacy and safety as a treatment for advanced renal cell carcinoma","volume":"13","author":"Ohba","year":"2024","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.phrs.2024.107181_bib57","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/1744666X.2016.1214575","article-title":"PD-1\/PD-L1 blockade in renal cell cancer","volume":"13","author":"Beckermann","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.phrs.2024.107181_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14369","article-title":"An unexpected N-terminal loop in PD-1 dominates binding by nivolumab","volume":"8","author":"Tan","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2024.107181_bib59","doi-asserted-by":"crossref","first-page":"67129","DOI":"10.18632\/oncotarget.18004","article-title":"Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2024.107181_bib60","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2024.107181_bib61","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2024.107181_bib62","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/cr.2016.102","article-title":"Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.phrs.2024.107181_bib63","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2024.107181_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1223929","article-title":"Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"14","author":"Krawczyk","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2024.107181_bib65","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2024.107181_bib66","doi-asserted-by":"crossref","first-page":"7051","DOI":"10.1002\/cam4.5504","article-title":"Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: a systematic review and network meta-analysis of safety","volume":"12","author":"Xie","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.phrs.2024.107181_bib67","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/bjc.2015.196","article-title":"Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma","volume":"113","author":"Gore","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2024.107181_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106156","article-title":"Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia","volume":"178","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2024.107181_bib69","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"issue":"Pt 2","key":"10.1016\/j.phrs.2024.107181_bib70","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.semcancer.2022.03.020","article-title":"The evolutionary legacy of immune checkpoint inhibitors","volume":"86","author":"Kaushik","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.phrs.2024.107181_bib71","doi-asserted-by":"crossref","first-page":"517","DOI":"10.20517\/cdr.2023.33","article-title":"Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma","volume":"6","author":"Astore","year":"2023","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.phrs.2024.107181_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102379","article-title":"Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations","volume":"105","author":"Iacovelli","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2024.107181_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113501","article-title":"The future of targeting cytotoxic T-lymphocyte-associated protein-4: is there a role?","volume":"198","author":"Di Giacomo","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2024.107181_bib74","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824001257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824001257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,28]],"date-time":"2024-04-28T03:37:08Z","timestamp":1714275428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824001257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":74,"alternative-id":["S1043661824001257"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107181","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107181","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107181"}}